^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LCAR-AIO

    i
    Other names: LCAR-AIO, Tri-specific CD19xCD20xCD22 VHH CAR-T cells
    Associations

    News

    Trials
    Company:
    Legend Biotech
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2years
    A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=34, Recruiting, Institute of Hematology & Blood Diseases Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    2years
    Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=34, Recruiting, Qiu Lugui
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    2years
    A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    over2years
    Tri-Specific CD19xCD20xCD22 VHH CAR-T Cells (LCAR-AIO) Eradicate Antigen-Heterogeneous B Cell Tumors, Enhance Expansion, and Prolong Persistence in Preclinical In Vivo Models (ASH 2021)
    Based on in vitro and in vivo preclinical data, tri-specific CD19xCD20xCD22 VHH CAR-T can be effective targeting tumors lack of CD19 expression, therefore, it has the potential of treating relapsed patients with prior CD19 CAR-T therapy. The feasibility of making tri-specific CAR-T would help to extend this technology to solid cancers where heterogeneity poses a major challenge at current stage.
    Preclinical • CAR T-Cell Therapy • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    CD20 expression • CD19 expression
    |
    LCAR-AIO